Editorial

Current and Future Prospects of Mesenchymal Stem Cells in Regenerative Medicine

Ghazala Butt, Assistant Professor of Dermatology, KEMU/ Mayo Hospital, Lahore

Introduction

A s stem cells have revolutionized all the fields of medicine in the present era so is the field of regenerative medicine which is the most recent and emerging branch of medical science and in which stem cells may prove to be a new armamentarium in treating di erent chronic and disabling diseases.

The self-renewal potential and the stem cells ability to di erentiate into di erent other type of specialized cells under appropriate conditions make them important in regenerative medicine. Stem cell research has shown that the diseases which could not be cured by conventional medicines can be treated by cell based therapies . Stem cells based therapies are newer, very promising and are gaining exceptional attention for treating di erent diseases.



Human Stem Cells Applications

There are many tissues from which mesenchymal stem cells (MSCs) can be obtained like skin, placenta, endometrium, peripheral blood, dental pulp, dermis, adipose tissue, amniotic fluid, umbilical cord blood as well as from tumors.¹ Cardiovascular, musculoskeletal, neurological, dermatological and many other diseases that have a limited capacity for repair can get benefit from stem cells therapy. Stem cells therapy has brought hope to the those who are su ering from

Jan - March 2019 | Volume 24 | Issue 1 | Page 928

distressing pathologies which involve di erent systems and organs of the body. Embryonic, mesenchymal stem cells and pluripotent cells which are induced are the predominant types of stem cells and currently only mesenchymal stem cells seems to be safe and are advised for di erent human pathologies involving di erent systems of the body.

MSCs can di erentiate into cells of mesodermal origin such as chondrocytes, muscle cells, osteocytes, adipocytes, into cells of ectodermal origin such as melanocytes and also into cells of endodermal origin such as liver cells so that they can be widely used for successful cellular therapy in di erent diseases.²⁻⁴ They secrete multiple growth factors like neural growth factors, vascular endothelial growth factors (VEGF), insulin like growth factors(IGF-1), brain derived neurotrophic factors(BDNF) etc, so these can target the a ected cells and play a major role in regenerative process as well as in degenerative diseases.⁵⁻⁷ MSCs play a significant role in certain neurodegenerative diseases. They have successfully been used in rat models of parkinson's disease, diabetic foot neuropathy, amyotrophic lateral sclerosis etc.8

MSCs can regenerate liver tissue so they can play an important role in liver cirrhosis management.⁹ Either stem cells can be directly transplanted or they can be first di erentiated and then they are transplanted. Osteogenic, chondrogenic and adipogenic potential of MSCs can be used as a therapeutic option in various orthopaedic injuries and diseases.¹⁰ For periodontal disease and di erent tooth injuries MSCs have been proved to play a role as a regenerative therapeutic option.¹¹ Various autoimmune diseases also respond to MSCs like systemic lupus erythema-

tosus, generalized systemic sclerosis, chronic graft versus host disease with cutaneous manifestations etc.¹²⁻¹⁴ Vitiligo which is an autoimmune disease can also be treated by using MSCs. Melanocytes stem cells (McSCs) or hair follicle stem cells (HFSCs) are present in the hair follicle outer root sheath (ORS). These HFSCs have a vast potential in the treatment of vitiligo as initial re-pigmentation often occurs around the hair follicles.

One of the application of MSCs in regenerative medicine is its use in di erent infectious diseases as the immune responses can be modulated by inflammatory cytokines which are secreted from the immune cells of the host, they attract MSCs to the site of inflammation.When inflammation occurs, MSCs migrate towards the site of injury, di erentiate into specialized cells mainly fibroblasts and release certain cytokines, growth factors and chemokines that can help in regeneration of injured tissues. Also MSCs can modify healing of injured tissues through anti-fibrotic, pro-angiogenic and anti-apoptotic pathways.¹²

Melanocyte stem cells (McSCs) are involved in melanoma as melanoma can descend in extrafollicular stem cells which are harmed by UVA and UVB.¹⁵ Di erent studies are being performed to find mechanisms which can cause damage to the stem cells DNA.^b

MSCs have also been used for the treatment of androgenetic alopecia and for other types of alopecia as well as for rejuvenation of aging skin. Di erent factors play their role in aging process and cause structural and functional damage with impaired signalling. Stem cells of the aged people do not function normally. Various mechanisms are involved in impaired function of stem cells in aged people such as defaults in DNA repair, accumulation of reactive oxygen species, epigenetic alterations and mitochondrial dysfunctions. All the above mechanisms are responsible for impaired function of stem cells in aged people.¹⁷ Rejuvenation and preservation of niches of stem cells can reverse aging manifestations.¹⁸

No considerable side e ects have been reported as far as safety profile is concerned in mesenchymal stem cells based therapies.So this therapy seems to be safe and e ective for the management of severe and refractory immune-mediated diseases. Patients su ering from various chronic diseases in which first line medications do not work can also get benefit from mesenchymal stem cells therapy.¹⁶

Studies on mesenchymal stem cells based therapies for di erent diseases are continuously increasing and applications of these therapies for treating various diseases is also exponentially increasing. But for the treatment of certain inherited and acquired disorders using stem cells based therapies, further research is required to observe their safety and e cacy.

Di erent studies are being carried out throughout the world also in Pakistan and it is thought to be a new armamentarium in the field of regenerative medicine. Regenerative medicine using stem cells has opened new avenues for di erent therapeutic strategies which are aimed at cell replacement as well as protection in various ischemic, traumatic and degenerative diseases. The ultimate aim should be to bring or translate stem cell based therapy to clinics thereby benefitting patients by curing their debilitating illnesses.

Stem cells based research represents great hope regarding regenerative therapeutic potential of stem cells in di erent fields of medicine. Although the existing therapeutic advancements of stem cells are more interventional, experimental and high in cost so due to this reason the application of stem cells based therapies may not be feasible under current circumstances but due to advancements in the medical science, in the near future stem cells may be used to treat autoimmune diseases, muscle damage, neurological disorders, genetic skin diseases, cancer etc. For the progression and advancement of certain translational applications of stem cells, there is indeed a dire need of various clinical trials in future. Funding from both public as well as private organizations may be required to accomplish this.

References

- 1. Roufosse CA, Direkze NC, Otto WR, Wright NA. Circulating mesenchymal stem cells. Int J Biochem Cell Biol. 2004;36:585–597.
- 2. Marfia G, Navone SE, Di Vito C, Ughi N, Tabano S, Miozzo M, et al. Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds. Organogenesis. 2015;11:183–206.

- 3. Krause D.S. Plasticity of marrow-derived stem cells.Gene Therapy 2002;9(11):754-8
- 4. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4
- Li Y,Chen J,Chen X.G,Wang L,Gautam S.C,Xu Y.X,et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002;59(4):514-23
- Zhang J, Li Y, Yang M, Katakowski M, Lu M, Chopp M. Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrowstromal cells. Brain res 2004;1030(1):19-27
- 7. Uccelli A,Benvenuto F,Laroni A,Giunti D. Neuroprotective features of mesenchymal stem cells:Best Pract Res Clin Haematol 2011;24(1):59-64
- 8. Forostyak S,Jendelova P,Kapcalova M,Arboleda D,Sykova E. Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis Cytotherapy 2011;13(9):1036-46
- 9. Volarevic V,Nurkovic J,Arsenijevic N, Stojkovic M.Concise review:therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis.Stem cells 2014;32(11):2818-23
- Csaki C, Matis U, Mobasheri A,Ye H,Shakibaei M.Chondrogenesis,osteogenesis and adipogenesis of canine mesenchymal stem cells:a biochemical,morphological and ultrastructural study. Histochem Cell Biol 2007;128(6):507-20
- 11. Oshima M,Tsuji T.Whole tooth regeneration as a

future dental treatment. Adv Exp Med Biol 2015; 881:255-69

- 12. Shin TH, Kim HS, Choi SW, Kang KS. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action. Int J Mol Sci. 2017;18:244
- Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009; 27:1421–32.
- 14. Yanez R, Lamana ML, García CJ, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006; 24: 2582–91.
- 15. Hoerter JD, Bradley P, Casillas A, Chambers D, Denholm C, Johnson K, et al. Extrafollicular dermal melanocyte stem cells and melanoma. Stem Cells Int. 2012;2012:407079.
- Ogliari KS, Marinowic D, Brum DE, Loth F. Stem cells in dermatology. An Bras Dermatol. 2014; 89: 286–291.
- 17. Krishnamurthy J, Sharpless NE. Stem cells and the rate of living cell.Stem Cell 2007;1:9–11.
- Kurtz A, Oh SJ. Age related changes of the extracellular matrix and stem cell maintenance. Prev Med 2012;54:50–S56.